肿瘤细胞被分成患者特异性cluster,与每个患者的基因组landscope一致。将突变和拷贝数改变映射到单个细胞上,通过比较肿瘤细胞的每个亚群与给定的 KRAS 突变的基因表达谱来测试 KRAS 热点变异的影响。含有KRAS G12V的肿瘤细胞会上调与更具侵袭性或转移性肿瘤相关的几个基因,包括COL1A1、VIM和 MUC5B。分析鉴定了5例具有多个KRAS 热点驱动的病例。在同一患者中携带不同 KRAS 驱动突变的两个不同的克隆在空间上分离,具有不同的基因表达谱。
To verify manually and/or determine the KRAS mutation status at KRAS hotspots G12, G13 and Q61, we used bam-readcount. For each case, we first applied bam-readcount to generate readcounts for each of the nine bases in these loci and then calculated VAF values of all the KRAS hotspots based on reference and alternative base read counts at each position. Additionally, we manually verified every variant present in a sample in a pairwise fashion against other samples within the same case.
We applied our in-house tool scVarScan that can identify reads supporting the reference and variant alleles covering the variant site in each individual cell by tracing cell and molecular barcode information in an scRNA bam file. For mapping, we used high-confidence somatic mutations from WES data. Additionally, we use http://cancerhotspots.org to obtain the most common KRAS hotspot mutations at G12, G13 and Q61, and use scVarScan to detect potential minority KRAS mutations in each sample.
For clarity, we assigned each cell, represented by a single dot in a UMAP plot, with only one genetic alteration, in a hierarchical fashion. For clarity and to not overcomplicate plotting due to too many comparison groups, if a mutation and a copy number event are detected in the same cell, the cell is labeled with the mutation. Additionally, when multiple mutations or copy number events are detected in the same cell, we plot them hierarchically as follows: KRAS > CDKN2A > SMAD4 > TP53.
原创声明:本文系作者授权腾讯云开发者社区发表,未经许可,不得转载。
如有侵权,请联系 cloudcommunity@tencent.com 删除。
原创声明:本文系作者授权腾讯云开发者社区发表,未经许可,不得转载。
如有侵权,请联系 cloudcommunity@tencent.com 删除。